The Expression and DNA-Binding Activity of NF-κB Nuclear Transcription Factor in the Tumors of Patients with Breast Cancer

Abstract

The content and DNA-binding activity of NF-κB nuclear transcription factor subunit p65 (NF-κBp65) were evaluated by quantitative enzyme immunoassay in tumors and histologically intact tissues of 119 patients with breast cancer. DNA-binding activity of NF-κBp65 in the tumors was higher than in adjacent tissue in 97% cases. This elevation was paralleled by an increase in total protein content in the majority of cases. No significant relationship of the parameter with the disease stage, tumor size and histology, and degree of lymph node involvement was detected. However, the content of NF-κBp65 in tumors of malignancy degree III was significantly higher than in tumors of malignancy degree II. An increase in total expression of NF-κBp65 protein was found in HER-2+ tumors. This increase was not related to steroid hormone receptor status and was not paralleled by elevation of DNA-binding activity, which was maximum in tumors with the "triple negative" receptor status (RE-RP-HER-2-).

FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling

“…As illustrated in Figure 1A, NF-κB was revealed as one of the most distinctive pathways in basal-like tumors. This is consistent with previous reports that sustained NF-κB activation exists mostly in human BLBC cell lines (23, 24) and ER-negative breast cancer (25) with its highest activity found in triple-negative tumors (26). NF-κB activity was also found to be essential for the proliferation and survival of BLBC cells (23).…”

Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via Suppressing MMP2/9 by Blocking NF-κB and ERK/MAPK Signaling Pathways

“…The transcription of MMPs is regulated by upstream sequences, including motifs corresponding to NF-κB. It is a transcription factor shown to be significantly increased in TNBC tumors, which is consistent with the aggressiveness of these tumors [ 35 ]. Our present results demonstrated that DATS inhibited NF-κB transcriptional activity.…”

Expression of Molecular Markers in Tumours of Patients with Breast Cancer

“…There are many contradictions in the results of such studies associated with absence of a standard method of determining the NF-κB activation, and the differences in interpretation of results obtained by the same method. However, most results suggest that NF-κB is activated mainly in ER-negative andHer2/neu-positive tumors [15,[18][19][20][21][22]. These tumors usually have a high proliferative index and Grade and form a group with the worst prognosis and high chemoresistance.…”